TRAW / Traws Pharma, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of

Exhibit 99.1 Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID® Separate single-arm trial will assess safety and efficacy in PAXLOVID®-in

NASDAQ: TRAW August 2025 Corporate Presentation

Exhibit 99.2 NASDAQ: TRAW August 2025 Corporate Presentation Forward - looking statements 2  This presentation contains, and certain oral statements made by management from time to time may contain, “forward - looking state ments” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 18, 2025 Traws Pharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 18, 2025 Traws Pharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 Traws Pharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 Traws Pharma, Inc.

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM)

Exhibit 99.1 Traws Pharma Reports Second Quarter 2025 Results and Business Highlights Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID, reflects the ongoin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Traws Pharma, Inc.

NASDAQ: TRAW August 2025 Corporate Presentation

Exhibit 99.2 NASDAQ: TRAW August 2025 Corporate Presentation Forward - looking statements 2  This presentation contains, and certain oral statements made by management from time to time may contain, “forward - looking state ments” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2025 Traws Pharma, Inc.

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to

Exhibit 99.2 Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path forward for accelerated approval of TXM for bird flu Phase 2 study prot

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2025 Traws Pharma, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2025 Traws Pharma, Inc.

NASDAQ: TRAW June 2025 Corporate Presentation

Exhibit 99.1 NASDAQ: TRAW June 2025 Corporate Presentation Forward - looking statements 2  This presentation contains, and certain oral statements made by management from time to time may contain, “forward - looking state ments” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Se

Traws Pharma - Rigosertib June 2025

Exhibit 99.1 Traws Pharma - Rigosertib June 2025 Forward - looking statements This presentation contains, and certain oral statements made by management from time to time may contain, “forward - looking state ments” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (th e “ Securities Act

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Exhibit 99.3 Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib NEWTOWN, PA, June 3, 2025 (GLOBE NEWSWIRE) – Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral

Traws Pharma Narazaciclib June 2025

Exhibit 99.2 Traws Pharma Narazaciclib June 2025 Forward - looking statements This presentation contains, and certain oral statements made by management from time to time may contain, “forward - looking state ments” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (th e “ Securities Act

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2025 Traws Pharma, Inc.

NASDAQ: TRAW May 2025 Corporate Presentation

Exhibit 99.1 NASDAQ: TRAW May 2025 Corporate Presentation Forward - looking statements 2  This presentation contains, and certain oral statements made by management from time to time may contain, “forward - looking state ments” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Sec

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2025 Traws Pharma, Inc.

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Exhibit 99.2 Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness NEWTOWN, PA, May 27, 2025 (GLOBE NEWSWIRE) – Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respirat

NASDAQ: TRAW May, 2025 Corporate Presentation

Exhibit 99.1 NASDAQ: TRAW May, 2025 Corporate Presentation Forward - looking statements 2  This presentation contains, and certain oral statements made by management from time to time may contain, “forward - looking state ments” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Se

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2025 Traws Pharma, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2025 Traws Pharma, Inc.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2025 Traws Pharma, Inc.

Traws Pharma Reports First Quarter 2025 Results and Business Highlights FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated

Exhibit 99.1 Traws Pharma Reports First Quarter 2025 Results and Business Highlights FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the “Animal Rule” Additional briefing document in support of a meeting to align on ratutrelvir for COVID - including

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Traws Pharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

Employment Agreement, effective April 1, 2025, by and between Traws Pharma, Inc. and Iain Dukes (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 18, 2025).

  Exhibit 10.1   TRAWS PHARMA, inc.   EMPLOYMENT AGREEMENT   This Employment Agreement (the “Agreement”) is entered into on April 16, 2025 by and between Traws Pharma, Inc., a Delaware corporation (the “Company”), and Iain Dukes (“Employee”). This Agreement shall be effective April 1, 2025. The date on which this Agreement becomes effective is referred to herein as the “Effective Date.”   WHEREAS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2025 Traws Pharma, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2025 Traws Pharma, Inc.

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2025 Traws Pharma, Inc.

Up to $7,427,749 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-273081 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 11, 2023 and Prospectus Supplement dated March 10, 2025) Up to $7,427,749 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated July 11, 2023 (the “Prospectus”), filed with the Securities and Exchange Commission as a part of our registration

Traws Pharma Reports Full Year 2024 Results and Business Highlights Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 d

Exhibit 99.1 Traws Pharma Reports Full Year 2024 Results and Business Highlights Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing FDA interaction to align on path forward for tivoxavir marboxil, including potential for accelerated approval utilizing the “

Form of Amendment to Pre-Funded Warrant, by and between Traws Pharma, Inc. and certain holders, dated March 27, 2025.

Exhibit 4.7 AMENDMENT TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT TRAWS PHARMA, INC. THIS AMENDMENT TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT (this “Amendment”), dated as of March 26, 2025, is being entered into by and between Traws Pharma, Inc., a Delaware corporation (the “Company”), and (the “Holder”), and amends that certain Pre-Funded Common Stock Purchase Warrant to purchase up to shares o

Consulting Services Agreement, by and between Traws Pharma, Inc. and Werner Cautreels, dated March 31, 2025.

Exhibit 10.47 Consulting Services Agreement This Consulting Services Agreement (“Agreement”) is made and entered into as of April 1, 2025 (“Effective Date”) between Traws Pharma, Inc. (“Company”) and Werner Cautreels (“Contractor”). In consideration of the mutual promises contained in this Agreement, the parties agree as follows: PAST ACTIVITIES FOR COMPANY All services performed by Contractor and

License Agreement, dated January 20, 2023, by and between Trawsfynydd Therapeutics, Inc. and Viriom, Inc.

Exhibit 10.36 LICENSE AGREEMENT This License Agreement (this “Agreement”), effective as of January 20, 2023 (“Effective Date”), is entered into by and between Viriom, Inc., a Delaware corporation having its corporate office at 12760 High Bluff Drive, Suite 370, San Diego, CA 92130 (“Licensor”), and Trawsfynydd Therapeutics, Inc., a Delaware corporation having its corporate office at 12760 High Blu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-360

Separation Agreement and Release of all Claims, by and between Traws Pharma, Inc. and Werner Cautreels, dated March 31, 2025.

Exhibit 10.46 SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS This Separation Agreement (“Agreement”) is made by and between Traws Pharma, Inc. (“Traws” or “Company”) and Werner Cautreels (“Cautreels” or “you”). In consideration for the execution of this Agreement, and the performance of the terms and conditions herein, Traws and Cautreels (collectively the “Parties”) agree as follows: Termination

Master Research and Development Agreement dated January 5, 2022, by and between Viriom, Inc and Trawsfynydd Therapeutics, Inc.

Exhibit 10.31 MASTER RESEARCH AND DEVELOPMENT AGREEMENT THIS AGREEMENT is made effective as of January 5, 2022 ("Agreement Date”) BETWEEN: 1. Full Name:Viriom, Inc. Address:12760 High Bluff Drive, Suite #370 San Diego, CA 92130 Tele phone:858-794-4860 (hereinafter referred to as "Viriom"); and 2.Full Name:Trawsfynydd Therapeutics Inc. Address:1209 Orange Street, Wilmington, DE 19801 Telephone:858-

Subsidiaries of Traws Pharma, Inc.

Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Onconova Europe GmbH Germany Trawsfynydd Therapeutics, LLC Delaware, U.S. Throxavir Therapeutics AU Pty Ltd Australia Trawsfynydd Therapeutics AU Pty Ltd Australia

Master Research and Development Agreement dated September 23, 2022, by and between ChemDiv, Inc. and Trawsfynydd Therapeutics, Inc.

Exhibit 10.33 MASTER RESEARCH AND DEVELOPMENT AGREEMENT THIS AGREEMENT is made effective as of 09/23/2022 (“Agreement Date”) BETWEEN: 1. Full Name: Address: ChemDiv, Inc. 12760 High Bluff drive, Suite 370 Telephone: San Diego, CA, 92130 858-794-4860 (hereinafter referred to as “CDI”); and 2. Full Name: Address: Telephone: Trawsfynydd Therapeutics, Inc. 1209 Orange Street, Wilmington, DE 19801 858-

Description of the Company’s Securities Registered under Section 12 of the Securities Exchange Act of 1934, as amended.

Exhibit 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES ACT OF 1934 The following is a summary of the material terms and provisions of the securities of Traws Pharma, Inc. (“us,” “our,” “we” or the “Company”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended, and certain provisions of our certificate of incorp

Master Research and Development Agreement dated September 1, 2022, by and between Expert Systems, Inc. and Trawsfynydd Therapeutics, Inc.

Exhibit 10.34 MASTER RESEARCH AND DEVELOPMENT AGREEMENT THIS AGREEMENT is made with an effective date of 09/01/2022 ("Agreement Date"); BETWEEN: 1. Full Name:Expert Systems, Inc. Address:12760 High Bluff Dr. Ste 370 San Diego, CA 92130 (hereinafter referred to as "Contractor"). 2. Full Name:Trawsfynydd Therapeutics, Inc. Address:1209 Orange St. Wilmington DE, 19801 (hereinafter referred to as "Cus

Investor Event March 31, 2025 Targeting Critical Threats to Human Health

Exhibit 99.2 Investor Event March 31, 2025 Targeting Critical Threats to Human Health Forward - looking statements 2  This presentation contains, and certain oral statements made by management from time to time may contain, “forward - looking state ments” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 Traws Pharma, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 Traws Pharma, Inc.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2025 Traws Pharma, Inc.

Traws Pharma Announces Management Updates

Exhibit 99.1 Traws Pharma Announces Management Updates · Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member · Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, PA, March 28, 2025 (GLOBE NEWSWIRE) – Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2025 Traws Pharma, Inc.

Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Exhibit 99.1 Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR · Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimen · Preparations are underway for FDA interactions and initiation of Phase 2 studies · Data presentation to be provided at the In

Poster Presentation, dated March 20, 2025.

Exhibit 99.2

Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates

Exhibit 99.1 Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates · Tivoxavir marboxil (TXM), administered as a single dose in non-human primates, significantly reduced lung viremia and prevented weight loss, two key measures of antiviral activity in preclinical bird flu models · Results build on earlier positive findings of mortality benefit for T

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 24, 2025 Traws Pharma, Inc.

Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Exhibit 99.1 Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR · Poster underscores Tivoxavir Marboxil’s potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent suppression of resistant viruses and Phase 1 data · Full dataset to be highlighted during Investor Call on March 31, 2025 at 10:00 AM ET NEWTOWN, PA, March 21, 202

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2025 Traws Pharma, Inc.

Tivoxavir marboxil, an Influenza Inhibitor Targeting Cap-dependent Endonuclease: Results from a Phase I Trial Demonstrating Safety, Tolerability and Pharmacokinetics and Demonstrating Protection Against H5N1 Bird Flu in a Rodent Challenge Model Ekate

Exhibit 99.2 Tivoxavir marboxil, an Influenza Inhibitor Targeting Cap-dependent Endonuclease: Results from a Phase I Trial Demonstrating Safety, Tolerability and Pharmacokinetics and Demonstrating Protection Against H5N1 Bird Flu in a Rodent Challenge Model Ekaterina Dokukina1 , Viktoriya Moskovich1 , Boris Rogovoy1 , Ruben Karapetian2 , Alexander Ivaschenko2 , Robert R. Redfield3 , Iain D. Dukes3

Up to $5,514,200 Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-273081 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 11, 2023) Up to $5,514,200 Common Stock We have entered into an at the market offering agreement (the “ATM Agreement”), with Citizens JMP Securities, LLC (“Citizens”), dated March 10, 2025, relating to the sale of shares of our common stock offered by this prospectus sup

At the Market Offering Agreement, by and between Traws Pharma, Inc. and Citizens JMP Securities, LLC (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 10, 2025).

Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT Up to $50,000,000 Shares of Common Stock March 10, 2025 Citizens JMP Securities, LLC c/o Citizens JMP Securities, LLC 450 Park Avenue, 5th Floor New York, NY 10022 Ladies and Gentlemen: Traws Pharma, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Citizens JMP Securities, LLC (the

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2025 Traws Pharma, Inc.

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Exhibit 99.1 Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil NEWTOWN, PA, March 3, 2025 (GLOBE NEWSWIRE) – Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 3, 2025 Traws Pharma, Inc.

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Exhibit 99.1 Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule NEWTOWN, PA, February 28, 2025 (GLOBE NEWSWIRE) – Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for the treatment of respiratory viral diseases, announced today that it has received confirmation from Nasdaq that Traws has regained compliance with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2025 Traws Pharma, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2025 Traws Pharma, Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 18, 2025 Traws Pharma, Inc.

Form of Amendment to Series A Common Stock Purchase Warrant, by and between Traws Pharma, Inc. and certain holders, dated February 18, 2025 (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on February 18, 2025).

Exhibit 4.1 FORM OF AMENDMENT TO SERIES A COMMON STOCK PURCHASE WARRANT TRAWS PHARMA, INC. THIS AMENDMENT TO SERIES A COMMON STOCK PURCHASE WARRANT (this “Amendment”), dated as of February 18, 2025, is being entered into by and between Traws Pharma, Inc., a Delaware corporation (the “Company”), and (the “Holder”), and amends that certain Series A Common Stock Purchase Warrant to purchase up to sha

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2025 Traws Pharma, Inc.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 18, 2025 Traws Pharma, Inc.

Offer Letter, by and between Traws Pharma, Inc. and Nora Brennan, dated February 5, 2025 (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on February 7, 2025).

Exhibit 10.2 February 5, 2025 Nora Brennan 402 Midland Avenue Wayne, PA 19087 Dear Nora, On behalf of Traws Pharma, Inc. (the “Company”), we are pleased to present you with this offer of at-will employment. Title: Interim Chief Financial Officer (Interim CFO) Reports to: Chief Executive Officer of the Company Job Classification: Full-Time FLSA Classification: Exempt Compensation: During the Interi

Separation Agreement and Release of all Claims, by and between Traws Pharma, Inc. and Mark Guerin, dated February 5, 2025.

Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS This Separation Agreement (“Agreement”) is made by and between Traws Pharma (“Traws” or “Company”) and Mark Guerin (“Guerin” or “you”). In consideration for the execution of this Agreement, and the performance of the terms and conditions herein, Traws and Guerin (each a “Party,” and collectively the “Parties”) agree as follows: 1.        

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2025 Traws Pharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul

Traws Pharma, Inc. 7,230,301 Shares Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(3)  Registration No. 333-284285 PROSPECTUS Traws Pharma, Inc. 7,230,301 Shares Common Stock This prospectus relates to the possible resale or other disposition from time to time, in one or more offerings, by the selling stockholders named in this prospectus of up to an aggregate of 7,230,301 shares of our common stock, par value $0.01 per share (“Co

JOINT FILING AGREEMENT

EX-99.1 2 ss4391465ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 2 to the Statement on Schedule 13D, dated December 31, 2024, with respect to the common stock of Traws Pharma, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 23, 2025 Traws Pharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 23, 2025 Traws Pharma, Inc.

Traws Pharma Announces Completion of Phase I studies with Tivoxavir marboxil, a single dose oral investigational drug for the treatment and prevention of H5N1 Bird Flu Phase I completed in healthy volunteers with pharmacokinetic data supporting dosin

Exhibit 99.1 Traws Pharma Announces Completion of Phase I studies with Tivoxavir marboxil, a single dose oral investigational drug for the treatment and prevention of H5N1 Bird Flu Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention NEWTOWN, PA, January 23, 2025 (PR NEWSWIRE) – Traws Pharma, Inc. (

Traws Pharma, Inc. 12 Penns Trail Newtown, PA 18940 (267) 759-3680

Traws Pharma, Inc. 12 Penns Trail Newtown, PA 18940 (267) 759-3680 January 17, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Traws Pharma, Inc. Registration Statement on Form S-3 Filed January 15, 2025 File No. 333-284285 REQUEST FOR ACCELERATION OF EFFECTIVENESS Ladies and Gentleman: Pursuant to Rule 46

As filed with the Securities and Exchange Commission on January 14, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 14, 2025 Registration No.

Calculation of Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Traws Pharma, Inc.

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval Initial tranche of $20 Million extends cash runway into 1H26, subsequen

Exhibit 99.1 Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval Initial tranche of $20 Million extends cash runway into 1H26, subsequent tranche of up to $52.6 Million will provide for runway 3+ years enabling the company to reach both near-term and long-term value inflec

Form of Pre-Funded Warrant

EXHIBIT 4.2 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Form of Series A Warrant

EXHIBIT 4.1 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC

Traws Pharma, Inc. 608,197 Shares of Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(4)  Registration No. 333-273081 PROSPECTUS SUPPLEMENT (To Prospectus dated July 11, 2023) Traws Pharma, Inc. 608,197 Shares of Common Stock We are offering 608,197 shares of our common stock to investors pursuant to this prospectus supplement and the accompanying prospectus and a securities purchase agreement with each investor. In a concurrent priv

Form of Securities Purchase Agreement

Exhibit 10.1 Form of SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 29, 2024, between Traws Pharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2024 Traws Pharma, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2024 Traws Pharma, Inc.

Form of Stockholder Support Agreement

EXHIBIT 10.2 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT Traws Pharma, Inc. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of December 29, 2024, is made by and among Traws Pharma, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of common stock, par value $0.01 per share (the “Shares”), of the Company. WHEREAS, Stockholder

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2024 Traws Pharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 20, 2024 Traws Pharma, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 20, 2024 Traws Pharma, Inc.

Trawsfynydd Therapeutics, Inc. 2021 Stock Plan.

  Exhibit 99.2   TRAWSFYNYDD THERAPEUTICS, INC. 2021 STOCK PLAN   ADOPTED ON DECEMBER 13, 2021     TABLE OF CONTENTS Page SECTION 1. ESTABLISHMENT AND PURPOSE 1 SECTION 2. ADMINISTRATION 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. ELIGIBILITY 1 (a) General Rule 1 (b) Ten-Percent Stockholders 1 SECTION 4. STOCK SUBJECT TO PLAN 2 (a) Basic Limita

Traws Pharma, Inc. 2021 Incentive Compensation Plan.

Exhibit 99.1 TRAWS PHARMA, INC. 2021 INCENTIVE COMPENSATION PLAN (As amended and restated, effective on the Restatement Effective Date) The purpose of the Traws Pharma, Inc. 2021 Incentive Compensation Plan (the “Plan”) is to provide employees of Traws Pharma, Inc. (fka Onconova Therapeutics, Inc.) (the “Company”) and its subsidiaries, certain consultants and advisors who perform services for the

As filed with the Securities and Exchange Commission on November 15, 2024

As filed with the Securities and Exchange Commission on November 15, 2024 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Traws Pharma, Inc.

Form of Inducement Restricted Stock Equity Award.

Exhibit 99.3 Traws Pharma, Inc. RESTRICTED STOCK UNIT AGREEMENT This RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”), dated as of April 1, 2024 (the “Date of Grant”), is delivered by Traws Pharma, Inc., f/k/a Onconova Therapeutics, Inc. (the “Company”) to [Participant Name] (the “Participant”). RECITALS Pursuant to the terms of the [Employment Agreement][/][Offer Letter] dated [], 2024 between

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Traws Pharma, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2024 Traws Pharma, Inc.

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Exhibit 99.1 Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results · COVID: Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, without ritonavir, and with a lower likelihood of clinical rebound and good overall tolerability · Flu: Phase 1 pharmacokinetic profile supports the potential for t

TRAW / Traws Pharma, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment

SC 13D/A 1 ss4087428sc13da.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Traws Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68232V 884 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VIII LLC 601 Lexington Avenue, 54th Floor New York, NY 10022

JOINT FILING AGREEMENT

EX-99.1 2 ss4087428ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated September 16, 2024, with respect to the common stock of Traws Pharma, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the u

Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2024 Traws Pharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 24, 2024 Traws Pharma, Inc.

TRAW / Traws Pharma, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment

SC 13D 1 ss3902792sc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Traws Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68232V 884 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VIII LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400

JOINT FILING AGREEMENT

EX-99.1 2 ss3902792ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated September 16, 2024, with respect to the common stock of Traws Pharma, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the u

Certificate of Amendment to Tenth Amended and Restated Certificate of Incorporation of Onconova Therapeutics, Inc., as amended, dated September 16, 2024 (Incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on September 17, 2024).

Exhibit 3.2 CERTIFICATE OF AMENDMENT TO TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TRAWS PHARMA, INC. TRAWS PHARMA, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Traws Pharma, Inc. The Tenth Amended and Restated Certificate of Incorporat

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders, Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2024 Traws Pharma, Inc.

Certificate of Amendment to Tenth Amended and Restated Certificate of Incorporation of Onconova Therapeutics, Inc., as amended, dated September 16, 2024 (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on September 17, 2024).

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TRAWS PHARMA, INC. TRAWS PHARMA, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Traws Pharma, Inc. The Tenth Amended and Restated Certificate of Incorporat

Traws Pharma, Inc. Announces Special Shareholders Meeting Results Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws’ shares expected to begin trading o

Exhibit 99.1 Traws Pharma, Inc. Announces Special Shareholders Meeting Results Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws’ shares expected to begin trading on a split-adjusted basis on September 23, 2024 NEWTOWN, PA, September 17, 2024 (GLOBE NEWSWIRE) – Traws Pharma, Inc. (Nasdaq: TRAW) (“Tra

Traws Pharma, Inc. 128,942,761 Shares Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(3)  Registration No. 333-280642 Prospectus Traws Pharma, Inc. 128,942,761 Shares Common Stock This prospectus relates to the possible resale or other disposition from time to time by the selling stockholders named in this prospectus of up to an aggregate of 128,942,761 shares of our Common Stock, par value $0.01 per share (“Common Stock”), which con

Traws Pharma, Inc. 12 Penns Trail Newtown, PA 18940

Traws Pharma, Inc. 12 Penns Trail Newtown, PA 18940 August 26, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Gama and Laura Crotty Re: Traws Pharma, Inc. Registration Statement on Form S-3 Filed July 1, 2024 File No. 333-280642 Ladies and Gentlemen: Pursuant to Rule 461 under the

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 23, 2024 Traws Pharma, Inc.

August 16, 2024

August 16, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE. Washington, D.C. 20549 Attention: Doris Stacey Gama and Laura Crotty Re: Traws Pharma, Inc. Registration Statement on Form S-3 Filed July 1, 2024 File No. 333-280642 Ladies and Gentlemen: Set forth below are the responses of Traws Pharma, Inc. (“we” or the “Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number 001- 36020 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number 001- 36020 NOTIFICATION OF LATE FILING (Check one:) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For period ended June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Fo

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Exhibit 99.1 Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical milestones, put Traws on track to achieve key readouts for the clinical pipeline in H2 2024 and beyond

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Traws Pharma, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2024 Traws Pharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ De

July 30, 2024

July 30, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE. Washington, D.C. 20549 Attention: Doris Stacey Gama and Laura Crotty Re: Traws Pharma, Inc. Preliminary Proxy Statement on Schedule 14A Filed June 27, 2024 File No. 000-36020 Ladies and Gentlemen: Set forth below are the responses of Traws Pharma, Inc. (“we” or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ De

Letter from Ernst and Young LLP

Exhibit 16.1 July 19, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We refer you to our previous letter dated May 22, 2024 that addressed Traws Pharma Inc.’s disclosure in the initial filing announcing the change in auditors. We have read Item 4.01 of Form 8-K dated July 19, 2024, of Traws Pharma, Inc. and are in agreement with the statements contai

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2024 Traws Pharma, Inc.

Calculation of Filing Fee Table

Exhibit 107 Traws Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity  Common Stock, par value $0.001

As filed with the Securities and Exchange Commission on July 1, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 1, 2024 Registration No.

Amendment to Amended and Restated Bylaws of the Traws Pharma, Inc., effective as of June 26, 2024 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 28, 2024).

Exhibit 3.1 AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BYLAWS OF TRAWS PHARMA, INC. The Amended and Restated Bylaws (“Bylaws”) of Traws Pharma, Inc. (the “Corporation”), are hereby amended as follows, effective June 26, 2024: 1. Section 2.3 of the Bylaws of the Corporation is hereby amended and restated in its entirety to read as follows: “At any meeting of the stockholders, the holders of shares

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 26, 2024 Traws Pharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      Filed by the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2024 Traws Pharma, Inc.

TRAWS PHARMA, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Exhibit 99.3 TRAWS PHARMA, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On April 1, 2024, Onconova Therapeutics, Inc., a Delaware corporation (the “Company”), acquired Trawsfynydd Therapeutics, Inc., a Delaware corporation (“Trawsfynydd”), in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the “Merger Agreement”), by and among the Company, Tra

Trawsfynydd Therapeutics, Inc. Financial Statements For the three months ended March 31, 2024 and 2023 TABLE OF CONTENTS

Exhibit 99.2 Trawsfynydd Therapeutics, Inc. Financial Statements For the three months ended March 31, 2024 and 2023 TABLE OF CONTENTS Financial Statements Condensed Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023 3 Condensed Statements of Operations for the three months ended March 31, 2024 and 2023 (unaudited) 4 Condensed Statements of Redeemable Convertible Preferred Stock

Trawsfynydd Therapeutics, Inc. Financial Statements As of and for the years ended December 31, 2023 and 2022 TABLE OF CONTENTS

Exhibit 99.1 Trawsfynydd Therapeutics, Inc. Financial Statements As of and for the years ended December 31, 2023 and 2022 TABLE OF CONTENTS Report of Independent Registered Public Accounting Firm (PCAOB ID Number 274) 3 Financial Statements Balance Sheets as of December 31, 2023 and 2022 4 Statements of Operations for the years ended December 31, 2023 and 2022 5 Statements of Redeemable Convertibl

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A Amendment No.

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2024 Traws Pharma, Inc.

Letter of EY

Exhibit 16.1 May 22, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated May 22, 2024, of Traws Pharma, Inc. and are in agreement with the statements contained in the first, second, third and fourth paragraphs on page 1 therein. We have no basis to agree or disagree with other statements of the registrant contained

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2024 Traws Pharma, Inc.

Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update Completed acquisition of Trawsfynydd and concurrent $14 million Capital Raise Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology

Exhibit 99.1 Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update Completed acquisition of Trawsfynydd and concurrent $14 million Capital Raise Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs Poised to initiate Phase 2 studies in H2 2024 for our influenza candidate and ritonavir-free COVID 19 protease inhibitor NEWTOWN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Traws Pharma, Inc.

Employment Agreement, dated April 12, 2024, by and between Traws Pharma, Inc. and Victor Mandla Moyo, MBChB.

Exhibit 10.5 TRAWS PHARMA, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) between Traws Pharma, Inc., a Delaware corporation (the “Company”) and Victor Mandla Moyo, MBChB. (“Employee”) is effective as of the date of the Employee’s commencement of employment with the Company, which is expected to be no later than April 12, 2024 (the “Effective Date”). WHEREAS, the Company des

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-3

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2024 Traws Pharma, Inc.

Potential best in class p roduct candidates in development for cancer & respiratory viral diseases April 2024 NASDAQ - TRAW

Exhibit 99.1 Potential best in class p roduct candidates in development for cancer & respiratory viral diseases April 2024 NASDAQ - TRAW Forward - looking statements This presentation contains, and certain oral statements made by management from time to time may contain, “forward - looking state ments” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform A

Investor Presentation, dated April 16, 2024

Exhibit 99.1 Potential best in class p roduct candidates in development for cancer & respiratory viral diseases April 2024 NASDAQ - TRAW Forward - looking statements This presentation contains, and certain oral statements made by management from time to time may contain, “forward - looking state ments” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2024 Traws Pharma, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2024 Traws Pharma, Inc.

Joint Filing Agreement among Viriom, Inc., Nikolay Savchuk and Iain D. Dukes

EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), each of the undersigned parties hereby agrees to file jointly the Schedule 13D (including any amendments thereto) (the “Statement”) with respect to the acquisition or disposition of shares of

ONTX / Onconova Therapeutics, Inc. / Viriom, Inc. Activist Investment

SC 13D 1 schedule13d.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Traws Pharma, Inc. (Name of Company) Common Stock, par value $0.01 per share (Title of Class of Securities) 68232V801 (CUSIP Number) Viriom, Inc. 12730 High Bluff Drive, Suite 100 San Diego, CA 92130 (858) 794-4860 (Name, Address and Telephone Number of Person Aut

Registration Rights Agreement, dated April 1, 2024, by and among the Onconova Therapeutics, Inc., OrbiMed and TorreyPines.

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of April 1, 2024, by and among Onconova Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2024 Traws Pharma, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2024 Traws Pharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2024 Traws Pharma, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2024 Traws Pharma, Inc.

Employment Agreement, dated April 1, 2024, by and between Onconova Therapeutics, Inc. and Werner Cautreels (Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on April 4, 2024).

Exhibit 10.3 ONconova therapeutics, inc. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into by and between Onconova Therapeutics, Inc., a Delaware corporation (the “Company”) and Werner Cautreels (“Employee”). This Agreement shall become effective upon the Closing (as defined in that certain Agreement and Plan of Merger, by and among the Company and Trawsfynydd Therap

Securities Purchase Agreement, dated April 1, 2024, by and among the Onconova Therapeutics, Inc., OrbiMed and TorreyPines (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 4, 2024).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 1, 2024, by and among ONCONOVA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A.            The Company and each Pur

Press Release of Traws Pharma, Inc.

Exhibit 99.1 Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company - Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey Pines - Funding expected to advance development of three potential best-in-class/class leading asset

Exhibit 2.1

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: Onconova Therapeutics, Inc., a Delaware corporation; TrawS MERGER SUB I, INC., a Delaware corporation; trawS MERGER SUB II, LLC, a Delaware limited liability company; and Trawsfynydd Therapeutics, Inc., a Delaware corporation dated as of April 1, 2024 Table of Contents Page SECTION 1. DESCRIPTION OF TRANSACTION 3 1.1 The Merger 3 1.2 Effects o

Employment Agreement, dated April 1, 2024, by and between Onconova Therpeutics, Inc. and Werner Cautreels.

Exhibit 10.3 ONconova therapeutics, inc. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into by and between Onconova Therapeutics, Inc., a Delaware corporation (the “Company”) and Werner Cautreels (“Employee”). This Agreement shall become effective upon the Closing (as defined in that certain Agreement and Plan of Merger, by and among the Company and Trawsfynydd Therap

Certificate of Designation of Series C Non-Voting Convertible Preferred Stock of Onconova Therapeutics, Inc., dated April 1, 2024.

Exhibit 3.1 onconova therapeutics, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Onconova Therapeutics, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly a

Certificate of Amendment to Tenth Amended and Restated Certificate of Incorporation of Onconova Therapeutics, Inc., as amended, dated April 2, 2024.

Exhibit 3.2 CERTIFICATE OF AMENDMENT TO TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ONCONOVA THERAPEUTICS, INC. Onconova Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the laws of the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY CERTIFY: 1. The name of the Corporation is Onconova Therapeutics, Inc. Th

Agreement and Plan of Merger, dated April 1, 2024, by and among the Onconova Therapeutics, Inc., Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd Therapeutics, Inc.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: Onconova Therapeutics, Inc., a Delaware corporation; TrawS MERGER SUB I, INC., a Delaware corporation; trawS MERGER SUB II, LLC, a Delaware limited liability company; and Trawsfynydd Therapeutics, Inc., a Delaware corporation dated as of April 1, 2024 Table of Contents Page SECTION 1. DESCRIPTION OF TRANSACTION 3 1.1 The Merger 3 1.2 Effects o

Form of Offer Letter

Exhibit 10.4 [Date] [Name of Prospective Employee] [Street Address of Prospective Employee] [City, State Zip of Prospective Employee] Dear [Name of Prospective Employee], On behalf of Onconova Therapeutics, Inc. (the “Company”), we are pleased to present you with this offer of at-will employment. This letter agreement (“Offer Letter”) shall become effective upon the Closing (as defined in that cer

Securities Purchase Agreement, dated April 1, 2024, by and among the Onconova Therapeutics, Inc., OrbiMed and TorreyPines.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 1, 2024, by and among ONCONOVA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A.            The Company and each Pur

Certificate of Designation of Series C Non-Voting Convertible Preferred Stock of Onconova Therapeutics, Inc., dated April 1, 2024 (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 4, 2024).

Exhibit 3.1 onconova therapeutics, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Onconova Therapeutics, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly a

Certificate of Amendment to Tenth Amended and Restated Certificate of Incorporation of Onconova Therapeutics, Inc., as amended, dated April 2, 2024 (Incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on April 4, 2024).

Exhibit 3.2 CERTIFICATE OF AMENDMENT TO TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ONCONOVA THERAPEUTICS, INC. Onconova Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the laws of the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY CERTIFY: 1. The name of the Corporation is Onconova Therapeutics, Inc. Th

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

Exhibit 99.1 Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company - Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey Pines - Funding expected to advance development of three potential best-in-class/class leading asset

Registration Rights Agreement, dated April 1, 2024, by and among the Onconova Therapeutics, Inc., OrbiMed and TorreyPines (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on April 4, 2024).

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of April 1, 2024, by and among Onconova Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities P

Form of Offer Letter (Incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on April 4, 2024).

Exhibit 10.4 [Date] [Name of Prospective Employee] [Street Address of Prospective Employee] [City, State Zip of Prospective Employee] Dear [Name of Prospective Employee], On behalf of Onconova Therapeutics, Inc. (the “Company”), we are pleased to present you with this offer of at-will employment. This letter agreement (“Offer Letter”) shall become effective upon the Closing (as defined in that cer

Subsidiaries of Onconova Therapeutics, Inc.

Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Onconova Europe GmbH Germany

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-360

Compensation Recoupment Policy of Onconova Therapeutics, Inc., dated as of December 1, 2023.

Exhibit 97 COMPENSATION RECOUPMENT POLICY OF ONCONOVA THERAPEUTICS, INC. Adopted to go into effect on December 1, 2023, with retroactive effectiveness to the Effective Date Section 1.Purpose. Onconova Therapeutics, Inc. (the “Company”) has adopted this Compensation Recoupment Policy (this “Policy”) to implement a mandatory clawback policy in the event of a Restatement in compliance with the applic

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming diff

Exhibit 99.1 Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational preparations for the narazaciclib program and the rigosertib trial plan expected in the f

Employment Agreement, dated as of October 2, 2023, by and between Onconova Therapeutics, Inc. and Victor Mandia Moyo, MBChB (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on November 14, 2023).

Exhibit 10.1 ONCONOVA THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) between Onconova Therapeutics, Inc., a Delaware corporation (the “Company”) and Victor Mandla Moyo, MBChB. (“Employee”) is effective as of the date of the Employee’s commencement of employment with the Company, which is expected to be no later than October 2, 2023 (the “Effective Date”). WHERE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2023 Onconova Therapeutics, Inc.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 25, 2023 Onconova Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 Onconova Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 Onconova Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 Onconova Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 Onconova Therapeutics, Inc.

Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results Anticipate topline results from the Phase 1 monotherapy and Phase 1/2 combination study with letrozole in Q4 2023 Plans are underway for a registration

Exhibit 99.1 Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results Anticipate topline results from the Phase 1 monotherapy and Phase 1/2 combination study with letrozole in Q4 2023 Plans are underway for a registrational trial with rigosertib in patients with RDEB-associated squamous cell carcinoma based on a constructive Type B FDA meeting held in June

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 21, 2023 Onconova Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 21, 2023 Onconova Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State

Onconova Therapeutics, Inc. 12 Penns Trail Newtown, PA 18940

Onconova Therapeutics, Inc. 12 Penns Trail Newtown, PA 18940 July 7, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Hamill Re: Onconova Therapeutics, Inc. Registration Statement on Form S-3 Filed June 30, 2023 File No. 333-273081 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933

As filed with the Securities and Exchange Commission on June 30, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 30, 2023 Registration No.

Filing Fee Table.

Exhibit 107 EX-FILING FEES Calculation of Filing Fee Table FORM S-3 (Form Type) Onconova Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

DEF 14A 1 tm2317674-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc.

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today

Exhibit 99.1 Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA. May 15, 2023 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today annou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 Onconova Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 Onconova Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2023 Onconova Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2023 Onconova Therapeutics, Inc.

By Electronic Delivery to: [email protected]

Exhibit 99.1 By Electronic Delivery to: [email protected] May 5, 2023 Mr. Mark Guerin Chief Operating Officer & Chief Financial Officer Onconova Therapeutics, Inc. 12 Penns Trail Newtown, PA 18940 Re: Onconova Therapeutics, Inc. (the “Company”) Nasdaq Symbol: ONTX Dear Mr. Guerin: On March 28, 2023, Staff notified the Company that its common stock failed to maintain a minimum bid price of $1.00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 3, 2023 Onconova Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 3, 2023 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36020 22-3627252 (State or other jurisdiction of incorporation) (Commissi

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

Exhibit 99.1 Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder NEWTOWN, PA April 6, 2023 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that its Chief Medical Officer (C

Subsidiaries of Onconova Therapeutics, Inc.

Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Onconova Europe GmbH Germany

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-360

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2023 Onconova Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2023 Onconova Therapeutics, Inc.

Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today

Exhibit 99.1 Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA., March 16, 2023 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2023 Onconova Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2023 Onconova Therapeutics, Inc.

Sent via Electronic Delivery to: [email protected]

Exhibit 99.1 Sent via Electronic Delivery to: [email protected] February 13, 2023 Mr. Mark Guerin Chief Operating Officer & Chief Financial Officer Onconova Therapeutics, Inc. 12 Penns Trail Newtown, PA 18940 Re: Onconova Therapeutics, Inc. (the “Company”) Nasdaq Security: Common Stock Nasdaq Symbol: ONTX Dear Mr. Guerin: On November 7, 2022, Staff notified the Company that its common stock fail

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2022 Onconova Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2022 Onconova Therapeutics, Inc.

Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

Exhibit 99.1 Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors NEWTOWN, PA., December 19, 2022 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D., and

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Onconova Therapeutics, Inc.

As filed with the Securities and Exchange Commission on November 15, 2022

As filed with the Securities and Exchange Commission on November 15, 2022 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2022 Onconova Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ? FORM 10-Q (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Commission file number: 001-36020 ? Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. 2021 Incentive Compensation Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on November 14, 2022).

Exhibit 10.1 ? ONCONOVA THERAPEUTICS, INC. ? 2021 INCENTIVE COMPENSATION PLAN ? (As amended and restated, effective on the Restatement Effective Date) ? The purpose of the Onconova Therapeutics, Inc. 2021 Incentive Compensation Plan (the ?Plan?) is to provide employees of Onconova Therapeutics, Inc. (the ?Company?) and its subsidiaries, certain consultants and advisors who perform services for the

Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update Initiation of Phase 1/2a endometrial cancer trial

Exhibit 99.1 Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update Initiation of Phase 1/2a endometrial cancer trial expected in 1Q23; preliminary data expected 4Q23 Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA., November 14, 2022

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 18, 2022 Onconova Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36020 Onconova Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2022 Onconova Therapeutics, Inc.

Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today

Exhibit 99.1 Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA., August 11, 2022 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX), (?Onconova?), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 21, 2022 Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Key Management Promotions Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of Corporate Development

Exhibit 99.1 Onconova Therapeutics Announces Key Management Promotions Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of Corporate Development NEWTOWN, Pa., June 13, 2022 (GLOBE NEWSWIRE) ? Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2022 Onconova Therapeutics, Inc.

Amendment to Employment Agreement, effective as of June 10, 2022, by and between Onconova Therapeutics, Inc. and Mark Guerin (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 13, 2022).

Exhibit 10.1 ONCONOVA THERAPEUTICS, INC. AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?), is made as of June 10, 2022 (the ?Amendment Effective Date?), by and between Onconova Therapeutics, Inc., a Delaware corporation (the ?Company?), and Mark Guerin (the ?Employee?). Capitalized terms used and not otherwise defined herein shall have the meanings ascrib

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ? FORM 10-Q (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Commission file number: 001-36020 ? Onconova Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2022 Onconova Therapeutics, Inc.

Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today

Exhibit 99.1 Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA., May 11, 2022 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX), (?Onconova?), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today anno

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-3

Subsidiaries of Onconova Therapeutics, Inc.

Exhibit 21.1 ? Subsidiary Jurisdiction of Incorporation Onconova Europe GmbH Germany ?

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-360

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2022 Onconova Therapeutics, Inc.

Onconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today

Exhibit 99.1 Onconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA., March 17, 2022 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX), (?Onconova?), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announ

ONTX / Onconova Therapeutics Inc / CVI Investments, Inc. - SC 13G/A Passive Investment

CUSIP No: 68232V801 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* Onconova Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 68232V801 (CUSIP N

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2022 Onconova Therapeutics, Inc.

Form of Non-Qualified Stock Option Agreement (Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on November 15, 2021).

Exhibit 10.2 ? ? ONCONOVA THERAPEUTICS, INC. 2021 INCENTIVE COMPENSATION PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT This NONQUALIFIED STOCK OPTION AWARD AGREEMENT (the ?Agreement?), dated as of the grant date set forth on the Stock Options Details page in Morgan Stanley Stock Plan Connect (the ?Date of Grant?), is delivered by Onconova Therapeutics, Inc. (the ?Company?) to the Participant on t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ? FORM 10-Q (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Commission file number: 001-36020 ? Onconova Therapeutics, Inc.

Form of Restricted Stock Unit Agreement (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on November 15, 2021).

Exhibit 10.1 ONCONOVA THERAPEUTICS, INC. 2021 INCENTIVE COMPENSATION PLAN RESTRICTED STOCK UNIT AGREEMENT This RESTRICTED STOCK UNIT AGREEMENT (the ?Agreement?), dated as of the grant date set forth on the Restricted Stock Units Details page in Morgan Stanley Stock Plan Connect (the ?Date of Grant?), is delivered by Onconova Therapeutics, Inc. (the ?Company?) to the Participant on the Restricted S

Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today

Exhibit 99.1 Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA., November 11, 2021 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX), (?Onconova?), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 11, 2021 Onconova Therapeutics, Inc.

ONTX / Onconova Therapeutics Inc / CVI Investments, Inc. - SCHEDULE 13G Passive Investment

CUSIP No: 68232V801 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. )* Onconova Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 68232V801 (CUSIP Nu

Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock

Exhibit 99.1 Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock NEWTOWN, PA., Sept. 24, 2021 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX) (?Onconova?), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the pricing of an underwritten public offering of 5,000,000 shares of its c

Underwriting Agreement, dated September 23, 2021, by and between Onconova Therapeutics, Inc. and Guggenheim Securities, LLC (Incorporated by reference as Exhibit 1.1 to the Company’s Current Report of Form 8-K filed on September 24, 2021).

Exhibit 1.1 Common Stock Onconova Therapeutics, Inc. UNDERWRITING AGREEMENT September 23, 2021 Guggenheim Securities, LLC As Representative of the several Underwriters named in Schedule I attached hereto c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen: Onconova Therapeutics, Inc., a corporation organized and existing under the laws of the State of De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 23, 2021 Onconova Thera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 23, 2021 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36020 22-3627252 (State or other jurisdiction of incorporation ) (Co

5,000,000 Shares Common Stock

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5) ?Registration No. 333-237844? PROSPECTUS SUPPLEMENT (To Prospectus dated May 18, 2020) 5,000,000 Shares Common Stock ? We are offering 5,000,000 shares of our common stock. We have granted the underwriters an option for a period of 30 days to purchase up to 750,000 additional shares of our common stock. Our common stock is listed on the Nasdaq Ca

SUBJECT TO COMPLETION, DATED SEPTEMBER 23, 2021

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer Preliminary Phase 1/2a trial data show an early signal of activity in exten

Exhibit 99.1 Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer Preliminary Phase 1/2a trial data show an early signal of activity in extensively pre-treated population with 2 partial responses out of 7 evaluable patients Responses were seen in patients with different KRAS mu

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2021 Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36020 22-3627252 (State or other jurisdiction of incorporation ) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 20, 2021 Onconova Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 20, 2021 Onconova Therapeutics, Inc.

Piper Sandler The date of this prospectus supplement is August 20, 2021

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-237844 PROSPECTUS SUPPLEMENT (To prospectus dated May 18, 2020) ONCONOVA THERAPEUTICS, INC. Up to $25,000,000 Common Stock We have entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler & Co., or Piper Sandler, relating to shares of our common stock offered by this prospectus

Equity Distribution Agreement, dated as of August 20, 2021, by and between Onconova Therapeutics, Inc. and Piper Sandler & Co. (Incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed on August 20, 2021).

Exhibit 1.1 ONCONOVA THERAPEUTICS, INC. EQUITY DISTRIBUTION AGREEMENT August 20, 2021 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this ?Agreement?), Onconova Therapeutics, Inc., a company organized under the laws of Delaware (the ?Company?), proposes to issue and sell from time to time through

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ? FORM 10-Q (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Commission file number: 001-36020 ? Onconova Therapeutics, Inc.

Employment Agreement, dated June 14, 2021, by and between Onconova Therapeutics, Inc. and Mark Stephen Gelder, M.D. (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on August 16, 2021).

Exhibit 10.1 ? ONCONOVA THERAPEUTICS, INC. ? EMPLOYMENT AGREEMENT ? This Employment Agreement (the ?Agreement?) between Onconova Therapeutics, Inc., a Delaware corporation (the ?Company?) and Mark Stephen Gelder, M.D. (?Employee?) is effective as of the date of the Employee?s commencement of employment with the Company, which is expected to be no later than June 14th, 2021 (the ?Effective Date?).

Employment Agreement, dated March 9, 2021, by and between Onconova Therapeutics, Inc. and Abraham N. Oler (Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on August 16, 2021).

Exhibit 10.2 ? ONCONOVA THERAPEUTICS, INC. ? EMPLOYMENT AGREEMENT ? This Employment Agreement (the ?Agreement?) is effective as of March 9, 2021 (the ?Effective Date?) between Onconova Therapeutics, Inc., a Delaware corporation (the ?Company?) and Abraham N. Oler (?Employee?). WHEREAS, the Company desires to employ Employee and Employee desires to be so employed by the Company upon the terms and c

Onconova Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today

Exhibit 99.1 Onconova Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., August 12, 2021 (GLOBE NEWSWIRE) ? Onconova Therapeutics, Inc. (NASDAQ: ONTX) (?Onconova?), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today a

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2021 Onconova Therapeutics, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K/A 1 tm2124162d28ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2021 Onconova Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36020 22-3627252

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2021 Onconova Therapeutics, Inc.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2021 Onconova Therapeutics, Inc.

As filed with the Securities and Exchange Commission on July 30, 2021

As filed with the Securities and Exchange Commission on July 30, 2021 Registration No.

Onconova Therapeutics, Inc. 2021 Incentive Compensation Plan, as approved by stockholders.

Exhibit 10.1 ONCONOVA THERAPEUTICS, INC. 2021 INCENTIVE COMPENSATION PLAN The purpose of the Onconova Therapeutics, Inc. 2021 Incentive Compensation Plan (the ?Plan?) is to provide employees of Onconova Therapeutics, Inc. (the ?Company?) and its subsidiaries, certain consultants and advisors who perform services for the Company or its subsidiaries, and non-employee members of the Board of Director

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2021 Onconova Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2021 Onconova Therapeutics, Inc.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 25, 2021 Onconova Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Letter from Nasdaq Dated June 17, 2021

Exhibit 99.2 By Electronic Delivery to: [email protected] June 17, 2021 Mr. Mark Guerin Chief Financial Officer Onconova Therapeutics, Inc. 375 Pheasant Run Newtown, PA 18940 Re: Onconova Therapeutics, Inc. (the ?Company?) Nasdaq Symbol: ONTX Dear Mr. Guerin: On May 11, 2021, Staff notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 con

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Exhibit 99.1 Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement NEWTOWN, Pa., June 22, 2021 (GLOBE NEWSWIRE) ? Onconova Therapeutics, Inc. (NASDAQ: ONTX) (?Onconova?), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that on June 17, 2021 it received a letter from The Nasdaq Stock Market LLC stating

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2021 Onconova Therapeutics, Inc.

Definitive Proxy Statement on Schedule 14A, filed with the SEC on May 28, 2021;

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Ru